Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.40 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6737153 | 0.91 | HRH3 (0.40) | HRH3CYP2D6CYP2C9HIF1AKDM4E | |
| SCHEMBL6733896 | 0.86 | HRH3 (0.59) | HRH3CYP2D6CYP2C9HIF1A | |
| SCHEMBL6740296 | 0.86 | HRH3 (0.44) | HRH3CYP2D6CYP2C9HIF1APTGER1 | |
| SCHEMBL6732800 | 0.85 | HDAC3 (0.37) | HRH3KDM4E | |
| SCHEMBL6732976 | 0.85 | HRH3 (0.41) | HRH3CYP2D6CYP2C9HIF1APTGER1 | |
| SCHEMBL6839627 | 0.83 | LMNA (0.37) | HRH3PTGER1KDM4E | |
| SCHEMBL6739873 | 0.82 | HRH3 (0.35) | HRH3KDM4E | |
| SCHEMBL6734242 | 0.82 | CYP2D6 (0.39) | HRH3CYP2D6CYP2C9HIF1A | |
| SCHEMBL6737938 | 0.81 | HRH3 (0.35) | HRH3KDM4E | |
| SCHEMBL6734999 | 0.81 | CYP2D6 (0.42) | HRH3CYP2D6CYP2C9HIF1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-01 | — | — | US | disclosed |
| US-20040122026-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20030225288-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | HRH3 530/4885RAPGEF3 2984/4885CYP2D6 685/4885 |
| US-20030225288-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | HRH3 530/4885RAPGEF3 2984/4885CYP2D6 685/4885 |
| US-20040122026-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | HRH3 530/4885RAPGEF3 2984/4885CYP2D6 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.